Skip to content
Review Open access

Deep brain stimulation (DBS): new targets for Parkinson's disease and obsessive-compulsive disorder

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Deep Brain Stimulation (DBS) is a neurosurgical procedure consisting of electrode implantation in specific brain regions for delivering electrical stimuli capable of modulating neuronal activity. Developed as an alternative to irreversible ablative techniques, it is an adjustable and reversible method. Its indications include movement disorders, such as Parkinson's Disease (PD), and psychiatric conditions, such as refractory Obsessive-Compulsive Disorder (OCD). PD, the second most prevalent neurodegenerative disease globally, is characterized by dopaminergic neuronal loss in the substantia nigra. Refractory OCD, present in 10% to 20% of cases, involves dysfunction in the Cortico-Striato-Thalamo-Cortical (CSTC) network. Both conditions demand the investigation of new targets and neuromodulation technologies. Objective: To analyze the new targets of Deep Brain Stimulation for Parkinson's Disease and Obsessive-Compulsive Disorder, including innovations such as adaptive stimulation and neural biomarkers, evaluating the clinical evidence supporting these approaches compared with traditional methods. Methods: Qualitative and descriptive literature review, with searches in SciELO, PubMed, and Google Scholar using the descriptors "Deep Brain Stimulation", "DBS", "Parkinson Disease", "Obsessive-Compulsive Disorder", and "OCD". The temporal scope comprised publications from 2020 to 2025. Randomized clinical trials, systematic reviews, meta-analyses, and multicenter studies on device evolution, new neuroanatomical targets, and neural biomarkers were included. Results: In PD, adaptive DBS (aDBS), based on real-time neural activity sensors, demonstrated superiority over the continuous model by automatically adjusting parameters according to the patient's neurophysiological state, reducing adverse effects and optimizing energy consumption. Beta and gamma band oscillations were validated as biomarkers for closed-loop systems. The INTREPID study confirmed significant clinical improvement (P<0.001) and a 28% reduction in medication burden after five years. In OCD, meta-analyses demonstrated reductions of 33% to 57% on the Y-BOCS scale, with temporal stability. The subthalamic nucleus was identified as a superior target for global functional recovery. However, international guidelines present significant heterogeneity, with an absence of consensus on programming parameters, while British guidelines restrict its use to research settings. Conclusion: DBS is consolidated in PD as a therapy of prolonged success, with advances toward adaptive closed-loop systems enabling precision neuromodulation. In OCD, although efficacy is validated by level-one evidence, challenges persist regarding protocol standardization, stigma surrounding brain interventions, and bureaucratic barriers classifying the technique as experimental. Greater investment is necessary in new targets and personalized approaches in OCD to potentiate the clinical benefits of DBS.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.